{
    "nctId": "NCT02655159",
    "briefTitle": "Study of Nab-paclitaxel (Abraxane\u00ae) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice",
    "officialTitle": "Retrospective Observational Study of Nab-paclitaxel (Abraxane\u00ae) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Neoplasms",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 46,
    "primaryOutcomeMeasure": "Overall response rate (ORR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women \u226518 years of age.\n* Confirmed diagnosis of MBC (stage IV).\n* Breast adenocarcinoma confirmed histologically.\n* HER2-negative according to the American Society of Clinical Oncology (ASCO) and Anatomical Pathology (CAP) criteria for the detection of HER2 in breast cancer.\n* Patients who have started treatment with nab-paclitaxel monotherapy no further than the third line of chemotherapy for metastatic disease in HER2-negative breast cancer during the period 2012-2014 (3 years) and who have received at least one cycle of treatment.\n* Ability to give informed consent, preferably in writing or orally in front of a witness, before the start of data collection (if it is able to be given).\n\nExclusion Criteria:\n\n* Patients with any medical or psychological disorder which in the investigator's opinion might compromise the ability of the patient to give their informed consent.\n* Patients who have received treatment with nab-paclitaxel combined with other chemotherapy agents or anti-angiogenic drugs or tumor-targeting drugs with anti-tumor activity.\n* Patients who have taken part in any clinical trial (interventional) during the study period.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}